An Illinois jury on July 30 refused to hold Johnson & Johnson liable for a woman’s death from ovarian cancer, which her family blamed on decades of using the company’s talc-based powders.
The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state’s attorney general said on July 20.
A founder of a Massachusetts compounding pharmacy whose mold-tainted drugs sparked a deadly U.S. fungal meningitis outbreak in 2012 was resentenced on July 7 to 14-1/2 years in prison after a federal appeals court overturned his earlier 9-year term.
In a countersuit, Cambridge, Mass.-based bluebird bio is hitting back at Roche-owned Spark Therapeutics over the use of the word “spark” in promotional campaigns involving the company’s “Be the Spark” campaign against sickle cell disease.
Novartis AG wants Roche Holding AG to return $210 million after accusing the company’s Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a lawsuit in U.S. District Court.
New York took Teva Pharmaceutical Industries and other companies – including the largest drug distributors in the United States – to trial on June 29, seeking to hold them liable for fueling an opioid crisis that has caused nearly half a million U.S. deaths over a decade.
The U.S. Supreme Court on June 17 rejected a Republican bid that had been backed by former President Donald Trump’s administration to invalidate Obamacare, preserving the landmark healthcare law for the third time since the ACA’s 2010 enactment.
United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.
Bristol Myers Squibb Co. was sued for $6.4 billion on June 3 for allegedly delaying the company’s Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp., which the drugmaker bought in 2019.
ReutersRussia’s Supreme Court on May 27 rejected a lawsuit from Gilead Sciences that challenged a Russian government decision to let a Russian firm develop and market the anti-Covid-19 drug remdesivir without the U.S. company ‘s consent.
